ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ANPC AnPac Bio Medical Science Company Ltd

4.37
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Name Symbol Market Type
AnPac Bio Medical Science Company Ltd NASDAQ:ANPC NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 4.37 4.22 4.65 0 01:00:00

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

16/05/2023 10:00pm

Edgar (US Regulatory)


 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May 2023

 

Commission File Number: 001-39137

 

Fresh2 Group Limited

 

650 5TH AVE STE 2416

NEW YORK, NY 10019-6108

United States

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒ Form 40-F  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

On May 16, 2023, the Registrant issued (i) a press release reporting the consolidated financial statements for the year ended December 31, 2022, (ii) a press release reporting the unaudited financial results for the three months ended March 31, 2023, and (iii) a press release reporting the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The Company's financial statements and related financial information for the three months ended March 31, 2023 are unaudited or have not been reviewed by the Company's independent registered accountant. These financial results could differ materially if they were reviewed by the Company’s independent registered accountant.

 

1

 

 

EXHIBIT INDEX

 

Exhibit   Description
99.1   Press release reporting the consolidated financial statements for the year ended December 31, 2022, dated May 16, 2023
99.2   Press release reporting the unaudited financial results for the three months ended March 31, 2023, dated May 16, 2023
99.3   Press release reporting the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2022, dated May 16, 2023

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Fresh2 Group Limited
   
  By: /s/ Haohan Xu
  Name:  Haohan Xu
  Title: Co-Chief Executive Officer
     
Dated: May 16, 2023    

 

 

3

 

 

1 Year AnPac Bio Medical Science Chart

1 Year AnPac Bio Medical Science Chart

1 Month AnPac Bio Medical Science Chart

1 Month AnPac Bio Medical Science Chart